Compounds
AssigneeAstraZeneca AB
InventorsPer Lennart Lindberg, Sverker von Unge
Life of this patent
Estimating the term…
Abstract
The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole or (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds.
Claims12
A pharmaceutical formulation for parenteral administration comprising an optically pure solid state Na.sup.+ salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole as active ingredient, and a pharmaceutically acceptable carrier.
A pharmaceutical formulation for parenteral administration comprising an injection solution comprising an optically pure solid state Na.sup.+ salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole as active ingredient, and a pharmaceutically acceptable carrier in the form of a pharmaceutically acceptable solvent having a volume sufficient to effect a solution having a concentration of 0.1 to 10% by weight of the active ingredient.
A method of inhibiting gastric acid secretion comprising the parenteral administration to a mammal including man in need of such treatment of a pharmaceutical formulation comprising a therapeutically effective amount of an optically pure solid state Na.sup.+ salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole and a pharmaceutically acceptable carrier.
A method for the treatment of gastrointestinal inflammatory disease comprising the parenteral administration to a mammal including man in need of such treatment of a pharmaceutical formulation comprising a therapeutically effective amount of an optically pure solid state Na.sup.+ salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole, and a pharmaceutically acceptable carrier.
A method of inhibiting gastric acid secretion comprising injecting a mammal including man in need of such treatment with a solution of an optically pure solid state Na.sup.+ salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole and a pharmaceutically acceptable solvent having a volume sufficient to effect a solution having a concentration of 0.1 to 10% by weight of the active ingredient.
A method for the treatment of gastrointestinal inflammatory disease comprising injecting a mammal including man in need of such treatment with a solution of an optically pure solid state Na.sup.+ salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole and a pharmaceutically acceptable solvent having a volume sufficient to effect a solution having a concentration of 0.1 to 10% by weight of the active ingredient.
Dependencies are inferred from the claim text.